Clofarabine

Nat Rev Drug Discov. 2005 May:Suppl:S12-3. doi: 10.1038/nrd1724.

Abstract

Clofarabine (Clolar; Genzyme), a purine nucleoside antimetabolite, was granted accelerated approval by the US FDA for the treatment of paediatric patients with relapsed or refractory acute lymphoblastic leukaemia in December 2004. It is the first new drug for paediatric leukaemia to be approved in more than a decade, and the only one to receive approval for paediatric use before adult use.

Publication types

  • Review

MeSH terms

  • Adenine Nucleotides
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Arabinonucleosides / administration & dosage
  • Arabinonucleosides / therapeutic use*
  • Child
  • Clinical Trials as Topic
  • Clofarabine
  • DNA / biosynthesis
  • Humans
  • Nucleic Acid Synthesis Inhibitors
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Ribonucleotide Reductases / antagonists & inhibitors
  • Treatment Outcome

Substances

  • Adenine Nucleotides
  • Antineoplastic Agents
  • Arabinonucleosides
  • Nucleic Acid Synthesis Inhibitors
  • Clofarabine
  • DNA
  • Ribonucleotide Reductases